Get started
Author

Uwe Rhein

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 122
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer
2021 · R. Charles Coombes, Holly Tovey, et al. · JAMA Oncology · 51
PDF
Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial)
2018 · RC Coombes, H Tovey, et al. · Cancer Research · 9
407P Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
2023 · J.C. Radosa, T. Fietz, et al. · Annals of Oncology · 3
PDF
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al. · Clinical Cancer Research · 2
[Integration of plastic surgery-esthetic aspects in surgical therapy of breast carcinoma].
1998 · H Graf, U Rhein, et al. · PubMed · 1
Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer in the real-world setting: Results from the PERFORM study.
2026 · Rupert Bartsch, Matthias Korell, et al. · Journal of Clinical Oncology
Effectiveness outcomes by treatment-free interval among patients receiving palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer in the real- world setting: Results from the PERFORM study
2026 · J Radosa, R Bartsch, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
462P Real-world effectiveness of 2nd-line treatments following 1L palbociclib + endocrine therapy: Preliminary results from the non-interventional study PERFORM
2026 · M.P. Lux, M. Korell, et al. · ESMO Open
PDF
Real-World-Wirksamkeit von Palbociclib+endokriner Therapie in der Erstlinie und nachfolgenden Behandlungen bei Patienten mit HR+/HER2- fortgeschrittenem Brustkrebs: Zwischenergebnisse der PERFORM-Studie
2026 · G Pfeiler, R Bartsch, et al. · Geburtshilfe und Frauenheilkunde
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
PERFORM
2025 · Rupert Bartsch, Matthias Korell, et al. · The Breast
519P Real-world effectiveness of 1st line palbociclib + endocrine therapy and subsequent treatments in patients with HR+/HER2- advanced breast cancer: Interim results from the PERFORM study
2025 · R. Bartsch, M. Korell, et al. · Annals of Oncology
Abstract P4-07-20: Is Distance to Treating Oncologist a Potential Prognostic Real-World-Factor for Patients with HR+/HER2- Advanced Breast Cancer? Results from the Non-Interventional Study PERFORM
2025 · Michael P Lux, Georg Pfeiler, et al. · Clinical Cancer Research
Differences in health-related Quality of Life in patients with or without progression on palbociclib therapy. Preliminary results from the Non-Interventional Study PERFORM
2025 · V Bjelic-Radisic, M Korell, et al. · Senologie - Zeitschrift für Mammadiagnostik und -therapie
Reduction mammaplasty using a modification of the Stroembeck‐method
2000 · U. Retzke, U. Rhein, et al. · International Journal of Gynecology & Obstetrics
Works count: 24
Citation count: 188
H-index: 3
I10-index: 2
Year
Topic
Type